Studies with Inhibitors of Leukotriene Biosynthesis with Special Reference to Piriprost (U-60,257)

  • Michael K. Bach
Part of the NATO ASI Series book series (NSSA, volume 95)


The underlying and motivating force behind the search for inhibitors of the formation of the leukotrienes is the hypothesis that these substances play an important if not an etiologic role in the elicitation of the symptoms of inflammation in general and of asthma in particular. An essential element in the final “proof” of this assumption is the demonstration that the selective inhibition of the formation or action of these substances can result in meaningful improvement in the condition of patients suffering from these disorders. Thus, even though relatively non-selective inhibitors may have their place, and even though in certain circumstances it may actually be desirable to combine the specific inhibition of certain pathways in one and the same molecule, the goal of the studies to be reported here is the development of selective inhibitors of the formation of the leukotrienes in the hope that these agents might then be useful in providing the remaining needed element of proof for the role of the leukotrienes in disease.


Sodium Cromoglycate Tantalum Powder Asthmatic Syndrome Preform Mediator Eicosanoid Pathway 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    M. K. Bach, J. R. Brashler, and R. R. Gorman, On the structure of slow reacting substance of anaphylaxis: Evidence of biosynthesis from arachidonic acid, Prostaglandins 14: 21 (1977).PubMedCrossRefGoogle Scholar
  2. 2.
    M. K. Bach, J. R. Brashler, H. W. Smith, F. A. Fitzpatrick, F. F. Sun, and J. C. McGuire, 6,9-deepoxy-6,9(phenylimino) -o6,8-prostaglandin I1, (U-60,257), a new inhibitor of leukotriene C and D synthesis: In vitro studies. Prostaglandins 23: 759 (1982).PubMedGoogle Scholar
  3. 3.
    D. M. Ritchie, J. N. Sierchio, R. J. Capetola, and M. E. Rosenthale, SRS-A-mediated bronchospasm by pharmacologic modification of lung anaphylaxis in vivo, Agents Actions 11: 396 (1981).PubMedCrossRefGoogle Scholar
  4. 4.
    M. K. Bach, R. L. Griffin, and I. M. Richards, Inhibition of the presumably leukotriene-dependent component of the antigen-induced bronchoconstriction in the guinea pig by piriprost (U-60,257), to be presented at the 15 Symposium of the Collegium Internationale Allergologicum, Puerto Vallarata, Mexico, September 1984.Google Scholar
  5. 5.
    H. G. Johnson, M. L. McNee, M. K. Bach, and H. W. Smith, The activity of a new, novel inhibitor of leukotriene synthesis in Rhesus monkey Ascaris reactors, Int. Archs Allergy Appl. Immunol. 70: 169 (1983).CrossRefGoogle Scholar
  6. 6.
    H. G. Johnson and M. L. McNee, Secretagogue responses of leukotrienes C4 and D4: A comparison of potency in canine trachea in vivo, Prostaglandins 25: 237 (1983).PubMedCrossRefGoogle Scholar
  7. 7.
    T. Ahmed, D. W. Greenblatt, S. Birch, B. Marchette, and A. Wanner, Abnormal mucocilliary transport in allergic patients with antigen-induced bronchospasm: Role of slow reacting substance of anaphylaxis. Am. Rev. Resp. Dis. 124: 110 (1981).PubMedGoogle Scholar
  8. 8.
    H. G. Jonson and M. L. McNee, Regulation of canine mucus secretion by a novel leukotriene synthesis inhibitor (U60,257), In Press.Google Scholar
  9. 9.
    M. K. Bach, J. R. Brashler, F. A. Fitzpatrick, R. L. Griffin, S. S. Iden, H. G. Johnson, M. L. McNee, J. C. McGuire, H. W. Smith, R. J. Smith, F. F. Sun, and M. A. Wasserman, In vivo and in vitro actions of a new selective inhibitor of leukotriene C and D synthesis. Adv. Prostaglandin Thromboxane Leukotriene Research 11:39 (1983).Google Scholar
  10. 10.
    R. J. Smith, F. F. Sun, B. J. Bowman, S. S. Iden, H. W. Smith and J. C. McGuire, Effect of 6,9-deepoxy-6,9(phenylimino)aA6,8 prostaglandin I1, (U-60,257), an inhibitor of leukotriene synthesis, on human neutrophil function, Biochem Biophys. Res. Commun.. 109: 943 (1982).CrossRefGoogle Scholar
  11. 11.
    M. K. Bach, J. R. Brashler and D. R. Morton, Jr., Solubilization and characterization of the leukotriene C4 synthetase of rat basophil leukemia cells: A novel, particulate glutathione S-transferase, Archs Biochem. Biophys. 230: 455 (1984).Google Scholar
  12. 12.
    F. F. Sun and J. C. McGuire, Inhibition of human neutrophil arachidonate 5-lipoxygenase by 6,9-deepoxy-6,9(phenylimino)6A6,8 prostaglandin I1 (U-60,257), Prostaglandins 26: 211 (1983).PubMedCrossRefGoogle Scholar
  13. 13.
    M. K. Bach, Prospects for the inhibition of leukotriene synthesis, Biochem. Parmacol. 33: 515 (1984)CrossRefGoogle Scholar
  14. 14.
    W. F. Stenson and E. Lobos, Sulfasalazine inhibits the synthesis of chemotactic lipids by neutrophils, J. Clin. Invest., 69: 494 (1982).PubMedCrossRefGoogle Scholar
  15. 15.
    R. P. Orange, M. D. Valentine, and K. F. Austen, Inhibition of release of slow reacting substance of anaphylaxis in the rat with diethylcarbamazine, Proc. Soc. Expt. Biol. Med.127: 127 (1968).Google Scholar

Copyright information

© Plenum Press, New York 1985

Authors and Affiliations

  • Michael K. Bach
    • 1
  1. 1.Department of Hypersensitivity Diseases ResearchThe Upjohn CompanyKalamazooUSA

Personalised recommendations